Trial Profile
A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Biliary cancer; Endometrial cancer; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Pigmented villonodular synovitis; Soft tissue sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
- 08 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 May 2023 Planned End Date changed from 1 Oct 2023 to 30 Jun 2023.
- 05 May 2023 Status changed from completed to active, no longer recruiting.